Last reviewed 2026-04-22 · How we verify

Asprin, Cilostazol

This combination of aspirin (antiplatelet) and cilostazol (phosphodiesterase-3 inhibitor) works synergistically to inhibit platelet aggregation and improve blood flow.

This combination of aspirin (antiplatelet) and cilostazol (phosphodiesterase-3 inhibitor) works synergistically to inhibit platelet aggregation and improve blood flow. Used for Secondary prevention of cardiovascular events in patients with peripheral arterial disease or coronary artery disease, Stroke prevention.

At a glance

Mechanism of action

Aspirin irreversibly inhibits cyclooxygenase (COX), reducing thromboxane A2 production and platelet aggregation. Cilostazol inhibits phosphodiesterase-3, increasing cAMP levels in platelets and vascular smooth muscle, further inhibiting platelet aggregation and promoting vasodilation. Together, they provide dual antiplatelet and vasodilatory effects.

Approved indications

• Secondary prevention of cardiovascular events in patients with peripheral arterial disease or coronary artery disease
• Stroke prevention

Common side effects

• Bleeding
• Headache
• Palpitations
• Gastrointestinal upset
• Diarrhea

Key clinical trials

• Prevention of Stroke Recurrence and Disease Progression in Cerebral Small Vessel Disease With Cilostazol (PHASE4)
• Cilostazol-Aspirin Therapy Against Recurrent Stroke With Intracranial Artery Stenosis (PHASE3)
• Effect of Cilostazol on Coronary Artery Stenosis and Plaque Characteristics in Patients With T2DM (PHASE3)
• Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White Matter Lesions (PHASE4)
• Effect of Cilostazol in the Acute Lacunar Infarction Based on Pulsatility Index of Transcranial Doppler (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.